MARKET

SNSS

SNSS

Sunesis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2784
-0.0163
-5.53%
Opening 13:43 07/09 EDT
OPEN
0.3050
PREV CLOSE
0.2947
HIGH
0.3050
LOW
0.2766
VOLUME
3.03M
TURNOVER
--
52 WEEK HIGH
1.130
52 WEEK LOW
0.1951
MARKET CAP
31.01M
P/E (TTM)
-1.1495
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNSS stock price target is 0.7500 with a high estimate of 1.000 and a low estimate of 0.5000.

EPS

SNSS News

More
Sunesis Pharmaceuticals Provides Corporate Update
GlobeNewswire · 1d ago
Sunesis Pharma announces 30% cut in headcount
Seeking Alpha - Article · 1d ago
Sunesis Pharma Reports Will Cut Workforce By ~30%
Benzinga · 1d ago
66 Biggest Movers From Thursday
Gainers GEE Group, Inc. (NYSE: JOB) shares climbed 199.9% to close at $1.54 on Thursday after the company eliminated over $47 million in debt and mezzanine financing.
Benzinga · 3d ago
Hedge Funds Are Selling Sunesis Pharmaceuticals, Inc. (SNSS)
Insider Monkey · 3d ago
Oppenheimer Downgrades Sunesis Pharmaceuticals to Perform
Oppenheimer downgrades Sunesis Pharmaceuticals (NASDAQ:SNSS) from Outperform to Perform.
Benzinga · 06/24 09:41
Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
GlobeNewswire · 06/23 12:30
Sunesis Pharma plunges 45% on vecabrutinib setback
Seeking Alpha - Article · 06/23 12:29

Industry

Biotechnology & Medical Research
-0.58%
Pharmaceuticals & Medical Research
-0.83%

Hot Stocks

Symbol
Price
%Change

About SNSS

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
More

Webull offers kinds of Sunesis Pharmaceuticals, Inc. stock information, including NASDAQ:SNSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNSS stock methods without spending real money on the virtual paper trading platform.